Presentations

Abstract

Introduction:

Approximately 70% of clinically diagnosed breast cancer cases are estrogen receptor (ER) positive. The interaction between ER, estrogen, and BRCA1 play a significant role in breast cancer prognosis. Mutations in the BRCA1 gene can significantly increase the risk of breast cancer. Tamoxifen, a selective estrogen receptor modulator, is a widely utilized treatment for these cancers; however, 50% of patients with advanced breast cancer do not exhibit a positive response to this medication at the onset of their treatment regimen, and another 40% of patients become resistant during treatment. This study aims to select and enrich cancer stem cells from various breast cancer cell lines and investigate the effects and mechanisms of the novel A7 compound on stem cell proliferation, migration, and differentiation. Stem cells are thought to play an important role in drug resistance.

Methods:

In the summer of 2023, MCF-7 and LCC9 cells were cultured, selected, and enriched for stem cells. These cultures were used to create 3-D cultures and treated with varying concentrations of the A7 compound. A Live-Dead Cell Viability Assay was conducted, and data was collected via a microplate reader and visualized with a fluorescence microscope.

Results:

The data indicated that A7 did not exhibit significant toxicity to MCF-7 and LCC9 cells in both epithelial and stem cancer cells.

Conclusion:

Further trials of A7 testing on cell growth in the presence of estrogen and testing of Tamoxifen as a control are needed to simulate regulation and confirm these findings. Additional investigation of ER+ cell lines with the mutant BRCA1 gene is also required. Further trials of A7 testing on cell growth in the presence of estrogen and testing of Tamoxifen as a control are needed to simulate regulation and confirm these findings. Additional study is required to investigate ER+ cell lines harboring the mutant BRCA1 gene.